A topical skin care composition for rejuvenation of the skin containing tetracaine, purified water, stearic acid, lauramide diethanolamine, beeswax, propylene glycol, sodium tetraborate, sodium lauryl sulfate, benzyl alcohol, glycerin, diazolidinyl urea, triethanolamine, methyl salicylate, and eucalyptus oil. The topical skin care composition of the invention is useful in the healing of the skin and in particular, after the skin has been exfoliated.

A topical skin care composition for rejuvenation of the skin containing tetracaine, purified water, stearic acid, lauramide diethanolamine, beeswax, propylene glycol, sodium tetraborate, sodium lauryl sulfate, benzyl alcohol, glycerin, diazolidinyl urea, triethanolamine, methyl salicylate, and eucalyptus oil. The topical skin care composition of the invention is useful in the healing of the skin and in particular, after the skin has been exfoliated.

A topical skin care composition for rejuvenation of the skin containing tetracaine, purified water, stearic acid, lauramide diethanolamine, beeswax, propylene glycol, sodium tetraborate, sodium lauryl sulfate, benzyl alcohol, glycerin, diazolidinyl urea, triethanolamine, methyl salicylate, and eucalyptus oil. The topical skin care composition of the invention is useful in the healing of the skin and in particular, after the skin has been exfoliated.

The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.

The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.

The present technology relates to synthesis of resveratrol compositions, in particular to methods of synthesizing resveratrol salicylates such as those formed through the activation of resveratrol and salicylic acid, and cosmetic and pharmaceutical compositions comprising the same.

The present technology relates to synthesis of resveratrol compositions, in particular to methods of synthesizing resveratrol salicylates such as those formed through the activation of resveratrol and salicylic acid, and cosmetic and pharmaceutical compositions comprising the same.

The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.